Hemostemix Closes Sale of 23rd ACP-01 Therapy Convertible Debenture
Hemostemix (OTCQB: HMTXF) has announced the closing of a sale of 15 ACP-01 Therapy Convertible Debentures (TCD) for USD $517,230, pending TSXV Exchange approval. The TCDs are convertible into ACP-01 therapy treatments or common shares at $0.155 per share, featuring a 6% annual interest rate payable in shares and a maturity date of December 31, 2029.
As an autologous stem cell therapy company, Hemostemix has successfully treated 498 patients for various cardiovascular diseases. The company's ACP-01 therapy has demonstrated clinical significance in treating conditions including peripheral arterial disease, chronic limb threatening ischemia, and various forms of heart disease. The new TCD structure enables the company to sell therapy blocks to clinics, investors, and high-net-worth individuals without diluting shareholder equity.
[ "Introduction of innovative TCD financing structure that allows forward sale of treatments without equity dilution", "Successfully treated 498 patients and completed 7 clinical studies with 318 subjects", "Demonstrated clinical significance in multiple cardiovascular conditions", "6% annual interest rate on TCDs provides additional value to investors" ]Hemostemix (OTCQB: HMTXF) ha annunciato la chiusura di una vendita di 15 Debentures Convertibili in Terapia ACP-01 (TCD) per un valore di USD $517.230, in attesa dell'approvazione della Borsa TSXV. Le TCD sono convertibili in trattamenti di terapia ACP-01 o in azioni ordinarie al prezzo di $0,155 per azione, con un tasso di interesse annuo del 6% pagabile in azioni e una scadenza fissata al 31 dicembre 2029.
Come azienda specializzata in terapie con cellule staminali autologhe, Hemostemix ha trattato con successo 498 pazienti affetti da diverse malattie cardiovascolari. La terapia ACP-01 dell'azienda ha dimostrato un'importanza clinica nel trattamento di condizioni quali la malattia arteriosa periferica, l'ischemia critica degli arti e varie forme di malattie cardiache. La nuova struttura TCD consente all'azienda di vendere blocchi di terapia a cliniche, investitori e individui con alto patrimonio netto senza diluire il capitale azionario.
- Introduzione di una struttura di finanziamento TCD innovativa che permette la vendita anticipata di trattamenti senza diluizione del capitale
- Trattamento con successo di 498 pazienti e completamento di 7 studi clinici con 318 soggetti
- Dimostrazione di rilevanza clinica in molteplici condizioni cardiovascolari
- Tasso di interesse annuo del 6% sulle TCD che offre un valore aggiunto agli investitori
Hemostemix (OTCQB: HMTXF) ha anunciado el cierre de una venta de 15 Debentures Convertibles en Terapia ACP-01 (TCD) por un total de USD $517,230, pendiente de la aprobación de la Bolsa TSXV. Los TCD son convertibles en tratamientos de la terapia ACP-01 o en acciones comunes a $0.155 por acción, con una tasa de interés anual del 6% pagadera en acciones y una fecha de vencimiento el 31 de diciembre de 2029.
Como empresa de terapia con células madre autólogas, Hemostemix ha tratado con éxito a 498 pacientes con diversas enfermedades cardiovasculares. La terapia ACP-01 de la compañía ha demostrado importancia clínica en el tratamiento de condiciones como la enfermedad arterial periférica, isquemia crítica de las extremidades y varias formas de enfermedades cardíacas. La nueva estructura de TCD permite a la empresa vender bloques de terapia a clínicas, inversores y personas con alto patrimonio sin diluir la participación accionaria.
- Introducción de una estructura innovadora de financiamiento TCD que permite la venta anticipada de tratamientos sin dilución de capital
- Tratamiento exitoso de 498 pacientes y finalización de 7 estudios clínicos con 318 sujetos
- Demostración de relevancia clínica en múltiples condiciones cardiovasculares
- Tasa de interés anual del 6% en los TCD que ofrece valor adicional a los inversores
Hemostemix (OTCQB: HMTXF)는 TSXV 거래소 승인 대기 중인 USD $517,230 규모의 15건 ACP-01 치료 전환 사채(TCD) 판매 완료를 발표했습니다. TCD는 주당 $0.155 가격으로 ACP-01 치료 또는 보통주로 전환 가능하며, 연 6% 이자율이 주식으로 지급되고 만기일은 2029년 12월 31일입니다.
자가 줄기세포 치료 회사인 Hemostemix는 다양한 심혈관 질환 환자 498명을 성공적으로 치료했습니다. 회사의 ACP-01 치료법은 말초 동맥 질환, 만성 사지 허혈, 여러 심장 질환 치료에서 임상적 중요성을 입증했습니다. 새로운 TCD 구조는 주주 지분 희석 없이 클리닉, 투자자, 고액 자산가에게 치료 블록을 판매할 수 있게 합니다.
- 지분 희석 없이 치료 선판매가 가능한 혁신적 TCD 금융 구조 도입
- 498명 환자 성공적 치료 및 318명 대상 7건 임상 연구 완료
- 다양한 심혈관 질환에서 임상적 중요성 입증
- TCD에 연 6% 이자율 적용으로 투자자에게 추가 가치 제공
Hemostemix (OTCQB : HMTXF) a annoncé la clôture de la vente de 15 débentures convertibles en thérapie ACP-01 (TCD) pour un montant de 517 230 USD, sous réserve de l'approbation de la bourse TSXV. Les TCD sont convertibles en traitements de thérapie ACP-01 ou en actions ordinaires au prix de 0,155 $ par action, avec un taux d'intérêt annuel de 6 % payable en actions et une date d'échéance au 31 décembre 2029.
En tant qu'entreprise spécialisée dans la thérapie par cellules souches autologues, Hemostemix a traité avec succès 498 patients atteints de diverses maladies cardiovasculaires. La thérapie ACP-01 de la société a démontré une importance clinique dans le traitement de pathologies telles que la maladie artérielle périphérique, l'ischémie critique des membres et diverses formes de maladies cardiaques. La nouvelle structure des TCD permet à l'entreprise de vendre des blocs de thérapie à des cliniques, des investisseurs et des particuliers fortunés sans diluer le capital des actionnaires.
- Introduction d'une structure de financement innovante par TCD permettant la vente anticipée de traitements sans dilution du capital
- Traitement réussi de 498 patients et réalisation de 7 études cliniques impliquant 318 sujets
- Démonstration de l'importance clinique dans plusieurs affections cardiovasculaires
- Taux d'intérêt annuel de 6 % sur les TCD offrant une valeur ajoutée aux investisseurs
Hemostemix (OTCQB: HMTXF) hat den Abschluss eines Verkaufs von 15 ACP-01 Therapie Wandelanleihen (TCD) im Wert von USD $517.230 bekannt gegeben, vorbehaltlich der Genehmigung durch die TSXV-Börse. Die TCDs sind in ACP-01 Therapien oder Stammaktien zu $0,155 pro Aktie wandelbar, bieten einen jährlichen Zinssatz von 6 %, der in Aktien zahlbar ist, und haben eine Fälligkeit am 31. Dezember 2029.
Als Unternehmen für autologe Stammzelltherapien hat Hemostemix erfolgreich 498 Patienten mit verschiedenen Herz-Kreislauf-Erkrankungen behandelt. Die ACP-01 Therapie des Unternehmens hat klinische Relevanz bei der Behandlung von peripherer arterieller Verschlusskrankheit, chronischer bedrohlicher Extremitätenischämie und verschiedenen Herzerkrankungen gezeigt. Die neue TCD-Struktur ermöglicht es dem Unternehmen, Therapieblöcke an Kliniken, Investoren und vermögende Privatpersonen zu verkaufen, ohne die Aktionärsanteile zu verwässern.
- Einführung einer innovativen TCD-Finanzierungsstruktur, die den Vorverkauf von Behandlungen ohne Eigenkapitalverwässerung ermöglicht
- Erfolgreiche Behandlung von 498 Patienten und Abschluss von 7 klinischen Studien mit 318 Teilnehmern
- Nachweis klinischer Bedeutung bei mehreren Herz-Kreislauf-Erkrankungen
- 6 % Jahreszins auf TCDs bietet zusätzlichen Wert für Investoren
- None.
- Transaction subject to TSXV Exchange approval
- Company paid CA$59,171 and issued 356,298 finder's warrants as transaction costs
- TCDs are unsecured obligations of the company
Calgary, Alberta--(Newsfile Corp. - July 23, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or "HEM"), an autologous angiogenic stem cell therapy company that has safely treated 498 patients for various forms of cardiovascular disease, including peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, angina, congestive heart failure and vascular dementia, announced, further to its prior news releases dated March 5, 2025 and June 26, 2025, the closing of the sale of 15 ACP-01 Therapy Convertible Debentures for proceeds of USD
"This is a breakthrough moment for Hemostemix," said Thomas Smeenk, CEO. "With the approval of our Therapy Convertible Debenture (TCD), we've ignited a new era-one where VesCell therapy can be sold forward, in blocks to clinics and investors, and directly to high net worth individuals. The TCD is a game-changer: It streamlines production, aligns treatment schedules with physician time, and powers our ability to scale fast-without diluting shareholder equity. As the global leader in autologous stem cell therapy for heart and peripheral arterial disease, Hemostemix is now positioned to monetize innovation that generates increased shareholder valuation-impacts," Smeenk said.
As an unsecured obligation of Hemostemix, each ACP-01 therapy convertible debenture ("TCD") is convertible into an ACP-01 therapy on a first purchased-basis. The TCD are transferable, saleable, subject to a right of first refusal by Hemostemix, will-able, and convertible into common shares of the Company ("Common Shares") at the option of the Purchaser. The conversion price of the TCDs is
The proceeds from the TCD will be used for general working capital, corporate overhead and research and development activities. The TCD is subject to a 4 month and one day hold from the date of issuance. In connection with the TCD offering, the Company paid an arm's length finder CA
ABOUT HEMOSTEMIX
Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), and later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). Hemostemix has treated 498 patients, completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia. For more information, please visit www.hemostemix.com.
For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder: EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to the closing of a non-brokered private placement, in furtherance of sales in Florida of VesCell™ (ACP-01), and the commercialization of ACP-01 via the sale of compassionate treatments under Florida SB 1768. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR+ website at www.sedarplus.ca. Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/259734
FAQ
What is the value and terms of Hemostemix's (HMTXF) latest convertible debenture sale?
How many patients has Hemostemix treated with its stem cell therapy?
What medical conditions does Hemostemix's ACP-01 therapy treat?
What are the key features of Hemostemix's new Therapy Convertible Debentures (TCDs)?
How will the TCD proceeds be used by Hemostemix?
